Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin in Youth with Autism
2024-512387-56-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Oslo University Hospital. Primary endpoints: Change in Social Responsiveness Scale-Second Edition (SRS-2) caregiver report and Change in Repetitive Behavior Scale-Revised (RBS-R) caregiver report. Planned start Oct 2024; status: authorised.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2024-512387-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512387-56-00.